10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M

10x Genomics, Inc.

2025-Q2 EPS reported $0.00 revenue$327,791,000

Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).
GAAP net income $34.5M vs net loss $37.9M YoY; operating income $30.1M.
Gross margin 72% vs 68% YoY; ex-license/royalty gross margin 67%.
Q3 2025 revenue guidance $140M-$144M, reflecting ~$4M China pull-forward.
Agreement to acquire Scale Biosciences for $30M upfront cash/stock plus milestone contingent consideration.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.